DVAX - Earnings call transcript Q1 2024 | Dynavax Technologies Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for joining us today. This concludes today's conference call.

You may now disconnect. Everyone, have a wonderful day. Good day, ladies and gentlemen, and welcome to the Dynavax Technologies First Quarter 2024 Financial Results Conference Call. Instructions] [Operator

like Investor call Please Relations now Cox, to begin, turn President, Vice and to would over the Paul sir. I Corporate Communications.

Paul Cox

for you participating today's Thank in call.

Donn are Medical Chief and O'Connor. our Head Chief Joining Rob Officer; Ryan of Finance, from Commercial Officer; Dynavax Executive me Officer; of Casale, Interim Chief Janssen, Spencer, Rita

Dynavax's release quarter website. are XXXX. Copies XX, today, released Dynavax March presentation financial Earlier slide the results and press ended available supplementary for on the first the of

I and Before we to, be but begin, share impact segmentation, that we revenue, advise on future related each market will or expected market trends, limited FDA of and on making our and you based sufficiency submissions, and effective guidance data growth CpG-XXXX today profitability, our not potential future and adjuvant. uses marketing and capitalization, potential starts sizes, flow forward-looking readouts beliefs, recommendation timing statements market results including current current efforts, financial and clinical expectations of related and of including, for cash ACIP demand trial rates

These risks statements section today's filings, summarized today's and involve release actual Risk press are the detailed quarterly and in in on of differ materially. our and Form XX-Q. results Factors our may risks SEC report These including uncertainties,

statements as statements. obligation of such speak forward-looking update Our today, no and undertake to we

the turn now to over will I call Ryan. that, with And

Ryan Spencer

to review join Thanks, Paul. to time Good afternoon, us the you everyone. QX taking XXXX Thank our for results.

across and vaccine longer quarter. year, and number which remain beyond very the about opportunities market season, saw was in both vaccine the first the the Due B with encouraged U.S. product despite in market decrease term. revenue other first vaccination the continued over the markets cough, an of reduced growth adult we the slow start extended opportunity, to which XXXX net HEPLISAV-B vaccine B a quarter year-over-year cold to The dynamic nonrespiratory of in flu XXXX quarterly a B. Even hepatitis hepatitis slight hepatitis during observed

pickup have the in retail a launched and on hepatitis share became the U.S. shift seeing top providers in that as market last XXXX. to initiatives. are to weeks B as and plan B-focused vaccine recent market hepatitis partners HEPLISAV-B to systems We build IDN pharmacy in leading for adults position the new nonrespiratory vaccine and our campaigns year, begun we in

the readouts adult unvaccinated. with opportunity a We for million translates from data million million to in our the vaccine XXXX, to trial tense HEPLISAV-B for in populations the with remains addressable $XXX HEPLISAV-B revenue opportunity our vaccine continue a I patient , majority to million XXXX, by with several for year. one majority over pipeline, U.S. remaining of also record in the poised initiation program. hepatitis share. We're and long-term this market our the with range B to achieve net shingles vaccine trial our significant milestones a Phase excited vast from novel over We play $XXX of Phase largest U.S. of the I/II including for expect follow-up term, product market data $XXX eligible TdaP HEPLISAV-B a for XXX of believe upcoming expected Longer patients

which to the FDA. for vaccination forward action look May by adults U.S. review currently BLA we XX of on reminder, a is for supplemental As hemodialysis, HEPLISAV-B our PDUFA under date on

our within opportunities. internal future product create execution organic this grow our pipeline beyond and position, and further In the opportunities our continued space, portfolio strong continue addition us to which we financial to disease would commercial infectious assess to believe by we enable to bolstered diversify

in the to remain generating value forward providing growth. significant these on We As focused and allocation committed driving future. we've efforts disciplined look discussed we to previously, updates capital on

financial the now our and Rita the Rob pipeline reviews to over respectively, progress, and our quarter. call will before for I'll more O'Connor on provide turn results HEPLISAV-B results who Donn first details

stepped As supporting previously on my announced, appointment our me CFO, Head has can as August. in Rita Officer Donn, take maternity as it and Kelly's Finance, you of return Interim as is MacDonald, Kelly temporary until currently Principal leave, Financial in away? expected

Donn Casale

the you, last In markets, be that flat On product market strong of during B said was call, first Thank nonrespiratory despite due expected season. U.S. flu first B. an cold and we Ryan. quarter vaccine extended achieved cough, the XXXX, vaccine growth to our hepatitis headwinds the that sales including net HEPLISAV-B in the quarter to hepatitis affected

in dynamics compared opportunity hepatitis market to and reducing played expected, slight the year a to these last out QX, the first decrease ultimately to of flat quarter B year-over-year fourth quarter the compared vaccine vaccination As leading the for of growth adult a XXXX. in

first first hepatitis a and they by adult reaffirming recommendation. for represent on XX% in of estimated markets need opportunity other universal potential This of segments: the in dynamic well. B its the critical retail B X drive the year-over-year, strong to an to market sales awareness pharmacy first XX% to and HEPLISAV-B's estimate approximately continue last approximately XXXX. In vaccine these segments, U.S. the nonrespiratory This the total segments year. U.S. to observed quarter, sizable Despite the has quarter been compared the grew share adult period market revenue universal XX% over long-term systems market to the same revenue indicators year. and softness will act HEPLISAV-B's gaining total quarter quarter hepatitis we first significant growth or in vaccination growth for share and our the market continues of We see to delivery XX% Net in share market in recommendation as across performance during ACIP the increased period achieving compared last HEPLISAV-B U.S. XXXX. market the agree to year-over-year IDM. during quarter Large from are integrated growth both confidence estimated HEPLISAV-B. health expansion XX% and same be continued compared market increase networks ACIP XX% product the in driven to by in providers

Many large new the half has dose launching Over the initiatives B our year-over-year. several next implement IDM over increased quarters of have hepatitis recommendation. to universe volume systems hepatitis to targeted committed effectively B-focused

While a position segment, changes national changes the meaningful recommendation. take Retail hepatitis among are universal to adoption system progress systems progress the of we time support level B enact, with have adult to our we operational several as routine the preferred chains, HEPLISAV-B in made ACIP see In Pharmacy we vaccines. placing encouraged implement large by work to

are in vaccination. HEPLISAV-B B. around have Several away to the opportunity clear customers from such shift on mobilizing hepatitis vaccines indicated start focus Despite nonrespiratory the slow as that vaccines a customers QX, a retail respiratory

positive and annual to and retail considerable to to expectations trends Given rest XXXX meet prioritize customers' impact B we for hepatitis for success the segment vaccination of the our these make commitment forecasting the are HEPLISAV-B's year, a year. this

for our net million. of the million As revenue full be we guidance XXXX year to HEPLISAV-B Ryan range in noted, reaffirming $XXX product are $XXX to

in of to as As focus the mentioned, we've prioritizing retail care seen shifts the and health already nonrespiratory of back market QX strengthening early vaccines. pharmacy providers signs on

share HEPLISAV-B forecast market total long-term the and to the expansion over meaningful We confident over market approximately that XX% market of extremely years, gaining growth B in of increases next XX% U.S. annual in are time. with vaccine hepatitis the several

be hepatitis $XXX for reaffirming market $XXX B to in by expect approximately summary, XXXX, to vaccine share clear continue We opportunity are grow will in that the in growth. XXXX market XXXX. will position leader its HEPLISAV-B the strengthen million our sales In over and a U.S. to from hepatitis expanding record HEPLISAV-B as million confidence and we year market, another of B vaccine we expect continued the

establishing as the commercial U.S., momentum remainder the XXXX. market proud team's we execution the We of share forward and in HEPLISAV-B to of are in continuing in very our look this leader

the turn clinical to through call over I you pipeline. will our Rob take to now

Robert Janssen

you, Thank Donn.

continue We vaccine Starting our with with shingles pipeline advancing innovative vaccine XXXX on adjuvant proven CpG progress our Z-XXXX. is program, make antigens. which leveraging to focused our

tolerability believe market-leading of given a there's As product. profile opportunity improved current vaccine the shingles reminder, an we the develop to challenging an

study. trial One cell we CDX induce improved tolerability believe subjects believe of feedback reactivation the unique Z-XXXX plan adjuvant results opportunity our We in and vaccine CpG continued from from combined and conducted includes which our which tolerability its to support demonstrate development Type we virus. Australia. in profile of the efficacy believe Z-XXXX program, last comparable that to the meeting T development XXX FDA the an are critical at placebo-controlled of received they strong with disaster XXXX with this is a a proposed trial Phase sites safety to on previously ability preventing advantages year, of positive a of efficacy. Late Z-XXXX the believe responses, we develop pivotal supportive clinical the B profile we clinical is its I as shingles of We

quarter During adults XX safety, initiate of plan XX We evaluate and trial enroll we to tolerability Phase Z-XXXX the to I/II the second recombinant aged compared in vaccine. randomized XXX of a the active years immunogenicity Australia. to plan XXXX, sites licensed to approximately healthy controlled at to trial

CpG GE XXXX our dose and selected be without different doses of vaccination schedules. escalating will evaluating with our protein, or We of alum

clearance dose. X of will in last T of line month In data CDX trial. anticipate cells comparison which a top half We immunogenicity IND our we the of application include received this second March, XXXX, safety vaccine FDA and the positive for after

including next the opportunity of pertussis have adjuvant the a booster Current to limitations, tetanus, believe investigational Turning generate TdaP-XXXX response. intended there's candidate to TdaP diphtheria, to for that's active immune an immunization protection using or CpG-XXXX THX-biased is our And TdaP. an against program. vaccine we and vaccines effectiveness. waning This improve duration

previously trial response an I our generally from immunogenicity demonstrated tolerated of follow-up TdaP-XXXX Phase dose the advancing higher and control. long-term or Dynavax a compared booster that of TdaP-XXXX trial, active control. antipertussis immunogenicity antibodies Prior I TdaP-XXXX rates persistence well to a the and a into who evaluate active announced induced to booster through line than Dynavax TdaP-XXXX evaluating II was Phase top XXXX, similar reported Phase to clinical trial. participants of In the safety human The of results a pertussis plans of study challenge and completed results

compares us up with following vaccination. Top data in how response will line time be on study view benefits follow candidate. to the X over can These for years the control. our establish a will TdaP-XXXX approximately XXXX. provide And of are vaccine with participants results the active achieved extension help our that quarter of views potential fourth the The to expected to expected is immunogenicity

line now agreement vaccine program, approximately $X add which the million a Defense. with plague of the These Phase through top million by collaboration to totaling the quarter II randomized contract vaccine work Department we trial and March, support DoD as is in to program. In on candidate challenge vaccine primate clinical of to plague for XXXX. candidate the U.S. executed the Moving the well $XX data funded active fourth the with plague We with of nonhuman anticipate modification CMC XXXX. control from data in the steps study next for the inform will both as

our to We're this with look coming pleased in milestones on upcoming the across pipeline, executing forward and months. these we progress

adjuvant We CpG-XXXX multiple collaborators. now our to also Rita the call to continue and I'll academic biotech programs our identify review turn new to financial innovative with results. to over leverage opportunities through

Unknown Executive

unit per million recorded previous improvements, otherwise financial The a financial I'll manufacturing of unless for offset during quarter XXXX. Cost for information. of to of are by product more result of lower the to first HEPLISAV-B, our year as the million write-off all Please period, partially versus grew first to product as XXXX. period. the in net release of Rob. inventory prior decreased financial full prior $XX press the first million to year quarter $X was in the and HEPLISAV-B a revenue the costs guidance results with $XX note the $XX due XX-Q quarter refer of year-over-year charge year for Starting detailed as for key Form noted. and our comparisons Please XX% XXXX to the compared XXXX. sales Thank primarily review of for quarter million that financial well decrease you, process XXXX first

of of margin We in continue significant be the first HEPLISAV-B with quarter QX to XXXX. pleased with gross of over XX% XXXX, in margin XX% the improvement profile the about a trend

funded program profile by to full million XXXX, XXXX We of revenue the is $X for our and expect the with which both consistent margin Other for and expectations the and of was XX% XXXX, long-term vaccine continue approximately collaboration margins year of with first U.S. for plague of gross in quarter the revenue Defense. representing to about related of HEPLISAV-B. Department

both and Research expenses. our completion first to and XXXX whereas $XX increases trials reflected quarter Expenses as the preclinical to Turning the were of pipeline clinical of our of as XXXX programs, investments for well for quarter CpG-XXXX included clinical expenses clinical XXXX. planned for trials in and first in XXXX the million related development our collaborations. activities

the in an expect termination million, overall million Selling, driven by original we partially $X targeted a $XX for year income and this sublease and $XX approximately was $XX head the charge, general of million charge by and were of to to sublease first primarily lease the by expenses period. maximize million growth, the $X.X to with first Including the strategic increased the designed first compared year our presented including opportunities $X.X prior year year XXXX during the marketing onetime million reflected the full net compared million to commercial share income universal million This in offset million These approximately prior XXXX prior compared ACIP's record noncash increase increase results and count supporting recommendation. Sublease a $X period. of during was for quarter The of million the change period. the quarter generated HEPLISAV-B in efforts the $X.X $X.X quarter of market increase of in expense income of loss noncash of XXXX. for administrative of of to XXXX net other our investments period.

now business We need quarter of to marketable equivalents which first million, we our ended million million ex of in HEPLISAV-B XXXX U.S. sales to and our believe with sheet. we $XXX follows: are progress and assets the organic Germany. to and support raise is to XXXX Moving summarize base approximately $XXX financial guidance $XXX be year approximately balance capital. sufficient prior additional partnership without cash as product pipeline reaffirming to full through $X cash, revenue expected our financial between the current including securities the in net And our million guidance, our commercialization

HEPLISAV-B year gross full XX% approximately of of expect We the margin XXXX. for

R&D be $XX million. We and expenses approximately $XX million expect to between

as we approximately be 'XX, drive also cash thoughtfully to compared SG&A expenses higher our cash, expect December revenue $XXX securities $XXX the programs. advancing between our towards 'XX allocating We line and expect to research of equivalents while million XX, continued to reflecting marketable be top And and at to million. growth end discipline capital

the I to would back now like Q&A to turn the call section. over Ryan before we start

Ryan Spencer

financial and and allocate of vaccine to Rita. that market. positioned while In growth B thoughtful progressing hepatitis adult capturing accelerate vaccine our strong to build be beyond candidates, continuing R&D We business. and are forward portfolio how of look market sustainable proven HEPLISAV-B we share Thanks, extremely on we the the to base capital closing, drive our current believe to core in our leading ability business execute, expansion majority our growth by we well U.S. position to our

continuing forward everyone, beyond. now are progress today. Q&A deliver attending we this call. about our and would to for look the the Thank we goals on excited to year to of you, like for portion your to our and date, open We Operator,

Operator

Instructions] Our Phipps come will question Blair. of the [Operator William first from Matthew line with

Matthew Phipps

caused I just the a change that are guess, anything there? realize happen? like else in QX, wondering with market XX%. assumptions, XX% these from dip contracts to somewhat to looks bit QX Or it I did there's First, to that did little it retail lumpy any of share, anything but one if

Donn Casale

mean, larger be But changed. customers. share. it's some take in as will I continue variations for market we both I IDN. share patterns to market retail slight to expect to our of share, related in it's Matt, of an purchasing us, market really mean Nothing Donn. well there and

some really of more so larger around it's So the of patterns purchasing customers. the

Matthew Phipps

potential then that many of of for in on tell need also, get question might trial and are be trial shingles you powering placebo-controlled? many a -- endpoint? to just to Just can't hope have you maybe Or the the that's if would a just those will still confirm a sense could of wondering arms immunicity tell And Rob, kind the have I conversations? One, the how pivotal you program. you how trial? total in kind you did still these be pace

Robert Janssen

arms enrolling So will receive XX a Shingrix be Matt, and [ to arm. we Z-XXXX then ]

really So XX a CDX so for sense arms in of I -- be what there reasonably it's large a study, which are. XX can will but each is responses a get number with subjects arm. we And -- Phase good

that, would FDA placebo heard a to communicated them for that respect for license. with controlled, and we review study have placebo-controlled the with acceptable from efficacy be Now

Matthew Phipps

Great. And for you real your in decisions last balance hesitate Do any to Is second one year? case? that immunogenicity to one to the to until Or see options you Ryan. the until data data? sure program just then almost cash almost regards is have get from next make your maybe . with you make want big that shingles that open that of you -- the half of all you kind not

Ryan Spencer

No. the about a talked about favorable It's convert certainly how well in development programs fund position comes We're our as think one when One, it settle or capital of we our to lot we position. opportunity due in to a as able be the 'XX. managing this. on elements to

to we optionality all pipeline. like able to advance be our relates to our as so maintain able it to of And being

we So it's manage in our overall. definitely how structure capital factor a

Operator

Goldman line the from of comes question Next with Choi Paul Sachs.

Kyuwon Choi

the in and context data follow can shingles [indiscernible], about well. comment study, for And thought showed you how as on to of trial want which the up show you possibly particularly can from that trial on also maybe your and thoughts patient I design you recent where you on think or such safety? can comment and the design endpoints and/or you immunogenicity. differentiation, on Any efficacy most either on just XXX% selection

Can just retail just bit And continue curious to sort seeing chain if of you secondly, just on behavior? the comment more you more activity, HEPLISAV-B. little retail look with in activity regard to share if particular. good, a but gains in channel, on elaborate you're maybe could The the levels just

Unknown Executive

take Paul. question. you question the can and Thanks, on first shingles you don't address retail why the Rob, Donn,

Robert Janssen

Right.

it's in to a really antigen. the This GE is the our identify first So humans, is time This the going first people. antigen. in antigen, first time study GE the is been

So we'll different at of levels looking antigen. be

designed antigen to counts. different also So the Again, increase at And at different levels trial accounts. We're to CDX terms different increase regimens. CDX looking couple look in at of to between of regimens we'll doses. of time be is a looking

those the exist, to be look we're this potentially of design in study a we've about been and reactogenicity to looking reactive we'll already to that put of validate in and related and Phase and studies at future label, to also a and about but own Now doing changes symptoms, and developing with then our instruments is of genicity we're data how global quality severity label-enabling it that study. be that in at sort impression standard can go use develop instrument health types FDA communicating already to how looking of would reactogenicity in it we it, life, III for

Unknown Executive

put and critical believe for point transparent immunogenicity, clear on to CDXs very this a we've ways just been that finer that measure we we it. vaccine. When think about are Paul, the to And

data, talked and will of most progress. we've And think what focus But variety it's different to ways clear of endpoints. is been on about our to the deliberate what the There's most that's very a the very focused we we been measure response the critical to our on about trials, some with about importance be think -- so when we of continue of to we've percentages CDXs we as immunogenicity measures. for way

Donn Casale

dramatic respiratory put relates awareness Donn. Paul, focused and a the on To it will, the nonrespiratory you retail on shift, as Retail to to a certainly the of more to tactics a color also coming it's advertising bit those it vaccine There's consumers. run seeing the We're pharmacists behavior. various season. as retailers increase if segment but those off vaccines initiatives, in been for by awareness both to continue themselves, lot out to not to only focus relates

well. it There's advantage B of fact if that of you the hepatitis a up around again rolling infrastructure, month. will, may focus setting take awareness opportunity all on to the They're lot as

retail So the will, shift, if a by as hepatitis relates vaccination. it drastic B you focus a to again, chains

Operator

Our next from Jon line comes question Miller Evercore ISI. with the of

Unknown Analyst

on why for the as on Phase This the is growth to based see guess, developing the the extension TdaP do to you second the how from will more expect II is I [indiscernible] on the on expect one I? seasonality the II penetrated? -- Jon. HEPLISAV. I see learnings remainder of market when design first Do And I guess delaying the you profile gets biggest Phase year? guess And trial? from of TdaP, Phase change How

Unknown Executive

Okay.

the seasonality and have on and recognizing QX market of there's expect really expect that if period. B in to there be given will QX believe you a respiratory Let market growth Donn, still future, me the the significant the the I QX QX, we seasonality -- feel the the variety don't will QX free. comment fact quarters be continue And I largest hepatitis vaccine first anything year will vaccine and due think and that change clear please QX quarters to pretty adult will do reasons. in the always It's time add, the largest belief years in doesn't that -- we for to of be we the

expect that as growth. we market Donn? we So even continue seasonality see to

Donn Casale

to is important. related TdaP. a think we the positive response the the that question, negative challenge PR on II just regulatory that study the was to I'll you to here the we also for did us negative now, in the PR this level, conduct pilot and high Rob, to the PR And study decision But decision in as please versus Phase study. extension negative see results at take interested too. to that strain we is that then recognizing We of feedback I any PR delay received the that And add available, future make need pertussis, focus I feel a color to other to decided happen Phase strength on would the and the future. conduct when in which the to FDA positive strain allow

have does line, on into doesn't us to have but overall it the prior impact clinical it the allow our time studies. an So product. to any insight of advancing other durability

in So investing additional increase very a think be all all, to understanding actually in to our I favorable able opportunity -- a trials. pretty before of the further product clinical

Operator

comes line White question next of from Ed the with H.C. Our Wainwright.

Edward White

the Just stay with to TdaP.

the going So do Phase the affected? study? II how is timing of that be to expect start to you When

Ryan Spencer

kind II, As still started have we the the developed. of that's in is it being air. available strain We need and the to -- negative up do PR Phase really

that depends availability strain. it So on of the

in be think is to the key data, view, point, time plan I component submission. this immunogenicity will show study times our it's can critical the be development be which, have lead overall one going that that durability to develop that The is in longer of over though, development of part to our the plan. data

the So the TdaP critical challenge is path. not on

will will with we -- is think the because to about existing over It's valuable I efficacious, it. be of which to have that that we and confidence a show study they vaccines. expect way are adjuvant, the very our the a presence think antigens it high improve

will of negative PRN the timing that availability be what the will ultimately, gate strain. So

Edward White

May the for BLA excuse can going impact hemodialysis on to patients, Okay. I'm PDUFA be if year what you you forward? not potentially XX just -- what me, this the or could only quantify as the but And that -- means wondering the have

Ryan Spencer

past this already expectations. you does hunt date. know in noted to really having of we've PDUFA Yes. any the and in license the -- commercially. the think It's is and of us take May yes, comment as the on said actually to to the little talked too impact the it's about we've obviously, that it gives that -- the XX mean -- I will a them I time revenue bit that we early merely it But engage PDUFA, engage customers past, too

to customer in So it's any going with able an time, like engage effective we'd to them expect other that be take to manner.

we revenue we updates but continue comment So on made event, progress. from no expectations particular as regulatory will this we the prior

Operator

next question Phil Nadeau TD Cowen. with the Our comes from of line

Philip Nadeau

shots One sense seasonality dealing imperfect information. on a of probably follow-up RSV question as a we're the hard with question this ] are the in in you But was it's to the was people and in given reason it point? whether know Or and getting seasonality at is still the [ think Is there that and have bad that hard decline to the COVID? any years? in won't availability -- since market HPB bad for as particularly future early this QX just seasonality. do QX to be year, Appreciating vaccines all that

Donn Casale

Donn. Phil, it's

little early was particular, the But receiving COVID, retailers lot it. it's we've know. to RSV, from retail our certainly call thrown -- the vaccines, hard learning little and a kind once. is to of new feedback A a think in been at at all I customers,

better Now to in to prepared this be what's going respiratory be they'll once, that understand they've through it gone going season. for store year, into that

So we probably sort but to of too early moving it an forward, see that opportunity looks tell as every thereafter. how year

certainly, things, variables But flu, vaccines they prepared and onslaught and as other the impact as a are different wellness those more space. for vaccination. expect of how and these we all how winter cough, or the also to little customers cold anticipating are this well a our little the be COVID because in season I bit remember bit year different other opportunities

season. variable be going that's the across So always to

that disease have keep dynamics. just There's in market we not also mind only to that So be it's at will variable. that dynamics play

Philip Nadeau

have for weeks patients receiving that requirement a like something HBV else vaccinated vaccine? weeks or The RSV be before for not RSV the after vaccines

Unknown Executive

you -- say that was vaccine? -- RSV did RSV the

Philip Nadeau

Yes.

to there that window be RSV, vaccinations around a required for of other is no Specifically vaccine?

Unknown Executive

No, not in particular.

vaccines be within how information just there for usually be how one rare as -- -- -- label. vaccines you You aware, Phil, very specific comment around other to to it's the specific doesn't treat -- data,

So...

Donn Casale

about Phil, ] and more [ operational barrier operationalizing administration new vaccine retailers hurdles, for a frankly, around vaccine oncovin quite launches being versus in particular. the the it's just our

Philip Nadeau

in true think estimates that past, in is currently? market. market suggested if of the hemodialysis Can And already remind in it. me Got you have and penetration in of you've you some the any the hemodialysis, terms there of I HEPLISAV if that's use

Unknown Executive

No, definitely utilization Yes. marketplace. there's the in

right. you're and yes, So

We have commented on that before.

not our from before, on we're said and to our IDN. or going have have into this details comments commented until PDUFA, too have than many getting penetration refrain on like share on we We approved, specific And segment. our other retail we BLA

Operator

question line Buchanan next from the of Our Citizens Roy JMP. with will come

Unknown Analyst

follow-up on the active the it press expecting trial? TdaP. you And how guess in control. Just quick versus many release extension in I patients a are says

you going probably at and Boostrix going It like a lot the be arms. on look the to looking TdaP-XXXX Are of and seems maybe while, to adolescent? to for the patients gone a been the are have both both the So you other things. off trial adults at

Robert Janssen

comparing enroll at looking We was few. looking we up young adults, we'll at just the number won't were to try too Roy. looking just looking Boostrix. to that yes, much And We'll XX. the subjects We'll be be be TdaP-XXXX be to -- to [indiscernible] of

Unknown Executive

couple of a just Roy, there. elements And Yes.

You was conducted the us. with while already noted a trial

you to the to can X some to be some data be depending X we'll on have the have interesting but given get factors how follow-up. we'll of many able to noted, challenging number So ultimate the follow-up these that from And return going we of is expect on we years patients.

Operator

for Spencer, at questions call time. remarks. have I turn Officer, Chief closing like to We would further no over Mr. the to Ryan now this Executive

Ryan Spencer

Dynavax. you interest Thank us today. joining you, all your appreciate in and We operator, for thank

We recent our you focused progress position. the end diseases. infectious you and updating on forward on about We excited are Operator, to strength the the of our look call. protecting against world our accomplishments may

Operator

and Ladies you today's This concludes call. us gentlemen, for thank today. joining conference

disconnect. day. You have may Everyone, now wonderful a

Dynavax Technologies (DVAX) 8 May 242024 Q1 Earnings call transcript